Back to Search

An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors

  • Protocol Number: 202211206
  • Principal Investigator: Adkins, Douglas
  • Cancer Types: Head & Neck

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions